Exact Mass: 419.26715920000004
Exact Mass Matches: 419.26715920000004
Found 290 metabolites which its exact mass value is equals to given mass value 419.26715920000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ethamoxytriphetol
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists
Dehydroxypaxilline
Dehydroxypaxilline is a metabolite of Emericella striata. Metabolite of Emericella striata
N-Palmitoyl tyrosine
C25H41NO4 (419.30354260000007)
N-palmitoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Hericerin
Hericerin is found in mushrooms. Hericerin is isolated from the edible lions mane mushroom (Hericium erinaceum). Isolated from the edible lions mane mushroom (Hericium erinaceum). Hericerin is found in mushrooms. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
Stearidonyl carnitine
C25H41NO4 (419.30354260000007)
Stearidonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Stearidonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoylcarnitine
C25H41NO4 (419.30354260000007)
(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Oleoyl Histidine
C24H41N3O3 (419.3147756000001)
N-oleoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Arachidonoyl Aspartic acid
C24H37NO5 (419.26715920000004)
N-arachidonoyl aspartic acid, also known as N-arachidonoyl aspartate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Aspartic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Aspartic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Aspartic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
11-Deoxycortisol-3-carboxymethyloxime
C23H33NO6 (419.23077580000006)
N-Formyl-Nle-Leu-Phe
C22H33N3O5 (419.24200880000006)
Adimolol
C25H29N3O3 (419.22088040000006)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid
C25H29N3O3 (419.22088040000006)
N-(2-Carboxyphenyl)retinamide
Dehydroxypaxilline
11,12,13-trihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-1H,2H,3H,4H,6aH,9H,10H,11H,12H,13H,14H,15H,15bH-cycloundeca[e]isoindole-1,15-dione
C24H37NO5 (419.26715920000004)
11-hydroxydaphnigracine|methyl (4SR,6RS,6RS,8aRS,9RS,10aRS,11SR)-2,3,4,5,5,6,6,7,8,8a,9,10-dodecahydro-6,6-dihydroxy-2-methyl-6-(1-methylethyl)-1H,4H-spiro{4,10a-methanopentaleno[1,6-cd]azonine-11,3-pyran}-9-carboxylate
C24H37NO5 (419.26715920000004)
MRE-269
C25H29N3O3 (419.22088040000006)
MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
C24H37NO5_(7E)-11,12,13-Trihydroxy-3-isobutyl-4,5,8-trimethyl-3,3a,4,6a,9,10,11,12,13,14-decahydro-1H-cycloundeca[d]isoindole-1,15(2H)-dione
C24H37NO5 (419.26715920000004)
CP-728663
C26H33N3O2 (419.25726380000003)
CONFIDENCE standard compound; INTERNAL_ID 506; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5898; ORIGINAL_PRECURSOR_SCAN_NO 5894 CONFIDENCE standard compound; INTERNAL_ID 506; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5936; ORIGINAL_PRECURSOR_SCAN_NO 5934 CONFIDENCE standard compound; INTERNAL_ID 506; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5937; ORIGINAL_PRECURSOR_SCAN_NO 5935 CONFIDENCE standard compound; INTERNAL_ID 506; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5952; ORIGINAL_PRECURSOR_SCAN_NO 5951 CONFIDENCE standard compound; INTERNAL_ID 506; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5960; ORIGINAL_PRECURSOR_SCAN_NO 5958 CONFIDENCE standard compound; INTERNAL_ID 506; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5960; ORIGINAL_PRECURSOR_SCAN_NO 5959
Ala Ala Lys Met
C17H33N5O5S (419.22022880000003)
Ala Ala Met Lys
C17H33N5O5S (419.22022880000003)
Ala Cys Lys Val
C17H33N5O5S (419.22022880000003)
Ala Cys Val Lys
C17H33N5O5S (419.22022880000003)
Ala Lys Ala Met
C17H33N5O5S (419.22022880000003)
Ala Lys Cys Val
C17H33N5O5S (419.22022880000003)
Ala Lys Met Ala
C17H33N5O5S (419.22022880000003)
Ala Lys Thr Thr
Ala Lys Val Cys
C17H33N5O5S (419.22022880000003)
Ala Met Ala Lys
C17H33N5O5S (419.22022880000003)
Ala Met Lys Ala
C17H33N5O5S (419.22022880000003)
Ala Thr Lys Thr
Ala Thr Thr Lys
Ala Val Cys Lys
C17H33N5O5S (419.22022880000003)
Ala Val Lys Cys
C17H33N5O5S (419.22022880000003)
Cys Ala Lys Val
C17H33N5O5S (419.22022880000003)
Cys Ala Val Lys
C17H33N5O5S (419.22022880000003)
Cys Gly Ile Lys
C17H33N5O5S (419.22022880000003)
Cys Gly Lys Ile
C17H33N5O5S (419.22022880000003)
Cys Gly Lys Leu
C17H33N5O5S (419.22022880000003)
Cys Gly Leu Lys
C17H33N5O5S (419.22022880000003)
Cys Ile Gly Lys
C17H33N5O5S (419.22022880000003)
Cys Ile Lys Gly
C17H33N5O5S (419.22022880000003)
Cys Lys Ala Val
C17H33N5O5S (419.22022880000003)
Cys Lys Gly Ile
C17H33N5O5S (419.22022880000003)
Cys Lys Gly Leu
C17H33N5O5S (419.22022880000003)
Cys Lys Ile Gly
C17H33N5O5S (419.22022880000003)
Cys Lys Leu Gly
C17H33N5O5S (419.22022880000003)
Cys Lys Val Ala
C17H33N5O5S (419.22022880000003)
Cys Leu Gly Lys
C17H33N5O5S (419.22022880000003)
Cys Leu Lys Gly
C17H33N5O5S (419.22022880000003)
Cys Val Ala Lys
C17H33N5O5S (419.22022880000003)
Cys Val Lys Ala
C17H33N5O5S (419.22022880000003)
Gly Cys Ile Lys
C17H33N5O5S (419.22022880000003)
Gly Cys Lys Ile
C17H33N5O5S (419.22022880000003)
Gly Cys Lys Leu
C17H33N5O5S (419.22022880000003)
Gly Cys Leu Lys
C17H33N5O5S (419.22022880000003)
Gly Ile Cys Lys
C17H33N5O5S (419.22022880000003)
Gly Ile Lys Cys
C17H33N5O5S (419.22022880000003)
Gly Lys Cys Ile
C17H33N5O5S (419.22022880000003)
Gly Lys Cys Leu
C17H33N5O5S (419.22022880000003)
Gly Lys Ile Cys
C17H33N5O5S (419.22022880000003)
Gly Lys Leu Cys
C17H33N5O5S (419.22022880000003)
Gly Leu Cys Lys
C17H33N5O5S (419.22022880000003)
Gly Leu Lys Cys
C17H33N5O5S (419.22022880000003)
Ile Cys Gly Lys
C17H33N5O5S (419.22022880000003)
Ile Cys Lys Gly
C17H33N5O5S (419.22022880000003)
Ile Gly Cys Lys
C17H33N5O5S (419.22022880000003)
Ile Gly Lys Cys
C17H33N5O5S (419.22022880000003)
Ile Lys Cys Gly
C17H33N5O5S (419.22022880000003)
Ile Lys Gly Cys
C17H33N5O5S (419.22022880000003)
Lys Ala Ala Met
C17H33N5O5S (419.22022880000003)
Lys Ala Cys Val
C17H33N5O5S (419.22022880000003)
Lys Ala Met Ala
C17H33N5O5S (419.22022880000003)
Lys Ala Thr Thr
Lys Ala Val Cys
C17H33N5O5S (419.22022880000003)
Lys Cys Ala Val
C17H33N5O5S (419.22022880000003)
Lys Cys Gly Ile
C17H33N5O5S (419.22022880000003)
Lys Cys Gly Leu
C17H33N5O5S (419.22022880000003)
Lys Cys Ile Gly
C17H33N5O5S (419.22022880000003)
Lys Cys Leu Gly
C17H33N5O5S (419.22022880000003)
Lys Cys Val Ala
C17H33N5O5S (419.22022880000003)
Lys Gly Cys Ile
C17H33N5O5S (419.22022880000003)
Lys Gly Cys Leu
C17H33N5O5S (419.22022880000003)
Lys Gly Ile Cys
C17H33N5O5S (419.22022880000003)
Lys Gly Leu Cys
C17H33N5O5S (419.22022880000003)
Lys Ile Cys Gly
C17H33N5O5S (419.22022880000003)
Lys Ile Gly Cys
C17H33N5O5S (419.22022880000003)
Lys Leu Cys Gly
C17H33N5O5S (419.22022880000003)
Lys Leu Gly Cys
C17H33N5O5S (419.22022880000003)
Lys Met Ala Ala
C17H33N5O5S (419.22022880000003)
Lys Ser Ser Val
Lys Ser Val Ser
Lys Thr Ala Thr
Lys Thr Thr Ala
Lys Val Ala Cys
C17H33N5O5S (419.22022880000003)
Lys Val Cys Ala
C17H33N5O5S (419.22022880000003)
Lys Val Ser Ser
Leu Cys Gly Lys
C17H33N5O5S (419.22022880000003)
Leu Cys Lys Gly
C17H33N5O5S (419.22022880000003)
Leu Gly Cys Lys
C17H33N5O5S (419.22022880000003)
Leu Gly Lys Cys
C17H33N5O5S (419.22022880000003)
Leu Lys Cys Gly
C17H33N5O5S (419.22022880000003)
Leu Lys Gly Cys
C17H33N5O5S (419.22022880000003)
Met Ala Ala Lys
C17H33N5O5S (419.22022880000003)
Met Ala Lys Ala
C17H33N5O5S (419.22022880000003)
Met Lys Ala Ala
C17H33N5O5S (419.22022880000003)
Ser Lys Ser Val
Ser Lys Val Ser
Ser Ser Lys Val
Ser Ser Val Lys
Ser Val Lys Ser
Ser Val Ser Lys
Thr Ala Lys Thr
Thr Ala Thr Lys
Thr Lys Ala Thr
Thr Lys Thr Ala
Thr Thr Ala Lys
Thr Thr Lys Ala
Val Ala Cys Lys
C17H33N5O5S (419.22022880000003)
Val Ala Lys Cys
C17H33N5O5S (419.22022880000003)
Val Cys Ala Lys
C17H33N5O5S (419.22022880000003)
Val Cys Lys Ala
C17H33N5O5S (419.22022880000003)
Val Lys Ala Cys
C17H33N5O5S (419.22022880000003)
Val Lys Cys Ala
C17H33N5O5S (419.22022880000003)
Val Lys Ser Ser
Val Ser Lys Ser
Val Ser Ser Lys
Hericerin
CAR 18:4
C25H41NO4 (419.30354260000007)
dicyclohexyl-[2-(2-methoxyphenyl)indol-1-yl]phosphane
C27H34NOP (419.23778840000006)
2-Methyl-4-(N-ethyl-N-benzyl)aminobenzoaldehyde-1,1-diphenylhydrazone
BUTYLACRYLATE-STYRENE-METHYLOLACRYLAMIDE-METHACRYLICACID
C23H33NO6 (419.23077580000006)
SNC 162
SNC162 is a delta-opioid receptor agonist with an IC50 of 0.94 nM. SNC162 has antidepressant-like effects and produces a selective enhancement of the antinociceptive effects of fentanyl in rhesus monkeys[1][2].
{(3s)-1-[5-(Cyclohexylcarbamoyl)-6-(Propylsulfanyl)pyridin-2-Yl]piperidin-3-Yl}acetic Acid
C22H33N3O3S (419.22425080000005)
C471 - Enzyme Inhibitor
1-Ethoxycarbonyl-d-phe-pro-2(4-aminobutyl)hydrazine
C21H33N5O4 (419.25324180000007)
Acetamide, N-[2-[(2-aminoethyl)methylamino]-5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]phenyl]-
4,5,6-Trihydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-9,12-diene-2,18-dione
C24H37NO5 (419.26715920000004)
N-icosanoyltaurine
C22H45NO4S (419.30691300000007)
A fatty acid-taurine conjugate derived from icosanoic acid.
3-(1H-imidazol-5-yl)-2-[[(E)-octadec-9-enoyl]amino]propanoic acid
C24H41N3O3 (419.3147756000001)
2-[(Z)-[17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-ylidene]amino]oxyacetic acid
C23H33NO6 (419.23077580000006)
(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoylcarnitine
C25H41NO4 (419.30354260000007)
N-acetylsphingosine 1-phosphate(2-)
C20H38NO6P-2 (419.24366180000004)
N-[2-(4-morpholinyl)ethyl]-2-(4-propan-2-yloxyphenyl)-4-quinolinecarboxamide
C25H29N3O3 (419.22088040000006)
2-[2,5-Diethoxy-4-(4-morpholinyl)anilino]-1-(4-methyl-1-piperidinyl)-1-propanone
C23H37N3O4 (419.27839220000004)
N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]cycloheptanecarboxamide
C26H33N3O2 (419.25726380000003)
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
N-(cyclohexylmethyl)-2-[(2S,3R,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
[1-[3-(4-Fluorophenoxy)propyl]-4-piperidinyl]-diphenylmethanol
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
(2S,3S,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]azetidine-1-carboxamide
C25H29N3O3 (419.22088040000006)
N-(cyclohexylmethyl)-2-[(2R,3S,6S)-3-[(3-fluorophenyl)carbamoylamino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(cyclohexylmethyl)-2-[(2S,3S,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(cyclohexylmethyl)-2-[(2S,3S,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
(2S,3R,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide
C25H29N3O3 (419.22088040000006)
(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
C25H29N3O3 (419.22088040000006)
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-[(E)-2-phenylethenyl]-2-(piperidine-1-carbonyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one
C25H29N3O3 (419.22088040000006)
N-(cyclohexylmethyl)-2-[(2R,3R,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(cyclohexylmethyl)-2-[(2R,3R,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
(2S,3S,4S)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide
C25H29N3O3 (419.22088040000006)
(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
C25H29N3O3 (419.22088040000006)
(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
C25H29N3O3 (419.22088040000006)
(2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide
C25H29N3O3 (419.22088040000006)
(1R,9S,10S,11S)-12-(cyclopropylmethyl)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
C25H29N3O3 (419.22088040000006)
N-[(5S,6R,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(5S,6S,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(5S,6S,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(4R,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(4S,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(4R,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
(2R,3S,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide
C25H29N3O3 (419.22088040000006)
1-[(1R,2aR,8bR)-4-[cyclohexyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone
C25H29N3O3 (419.22088040000006)
(1S,9R,10R,11R)-12-(cyclopropylmethyl)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
C25H29N3O3 (419.22088040000006)
[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone
C25H29N3O3 (419.22088040000006)
(6S,7R,8R)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C25H29N3O3 (419.22088040000006)
(6R,7S,8S)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C25H29N3O3 (419.22088040000006)
cyclohexyl-[(2R,3S)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
C25H29N3O3 (419.22088040000006)
cyclohexyl-[(2S,3S)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
C25H29N3O3 (419.22088040000006)
N-[(5R,6R,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(5R,6R,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(5R,6S,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(5R,6S,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(4R,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(4S,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(4R,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-[(4S,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C22H33N3O5 (419.24200880000006)
N-(cyclohexylmethyl)-2-[(2S,3R,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
N-(cyclohexylmethyl)-2-[(2R,3S,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetamide
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
C22H33N3O5 (419.24200880000006)
(2R,3R,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide
C25H29N3O3 (419.22088040000006)
1-[(1R,2aS,8bS)-4-[cyclohexyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone
C25H29N3O3 (419.22088040000006)
1-[(1S,2aS,8bS)-4-[cyclohexyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone
C25H29N3O3 (419.22088040000006)
1-[(1S)-1-(hydroxymethyl)-7-methoxy-1,9-dimethyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-phenylethanone
C25H29N3O3 (419.22088040000006)
1-[(1R)-1-(hydroxymethyl)-7-methoxy-1,9-dimethyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-phenylethanone
C25H29N3O3 (419.22088040000006)
[(1R)-1-(hydroxymethyl)-7-methoxy-1-methyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone
C25H29N3O3 (419.22088040000006)
[(1S)-1-(hydroxymethyl)-7-methoxy-1-methyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone
C25H29N3O3 (419.22088040000006)
(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C25H29N3O3 (419.22088040000006)
(6S,7S,8R)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C25H29N3O3 (419.22088040000006)
(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C25H29N3O3 (419.22088040000006)
(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
C25H29N3O3 (419.22088040000006)
cyclohexyl-[(2R,3R)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
C25H29N3O3 (419.22088040000006)
cyclohexyl-[(2S,3R)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
C25H29N3O3 (419.22088040000006)
(E)-3-hydroxy-2-(undecanoylamino)dec-4-ene-1-sulfonic acid
C21H41NO5S (419.2705296000001)
(E)-2-(decanoylamino)-3-hydroxyundec-4-ene-1-sulfonic acid
C21H41NO5S (419.2705296000001)
ETHAMOXYTRIPHETOL
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists
ACT-333679
C25H29N3O3 (419.22088040000006)
A member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension.
N-acetylsphingosine 1-phosphate(2-)
C20H38NO6P (419.24366180000004)
A N-acylsphingosine 1-phosphate(2-) in which the N-acyl group is specified as acetyl; major species at pH 7.3.
SPHP(22:1)
C22H46NO4P (419.31642860000005)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
SPHP(21:2)
C21H42NO5P (419.2800452000001)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
GLX481304
GLX481304 is a specific inhibitor of Nox-2 and -4, with IC50s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart[1].